The results indicated that the potent anti-inflammatory effects of the dual-targeting nanoformulation against ischemic stroke might attribute to its blockade of HMGB1/TLRs/MyD88/TRIF/NF-κB signaling pathways. The gene discussed is NFKB1; the disease is ischemic stroke.